Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Zylö Therapeutics

Request full access

Offers an innovative sustained-release drug-delivery system

Greenville, United StatesFounded 2017Biotech & Life Sciences

About Zylö Therapeutics

Zylö Therapeutics, established in 2017, is a life sciences company commercializing a topical drug delivery platform. The firm was founded by Scott Pancoast, who serves as CEO and brings extensive experience from the venture capital and biotech sectors, having previously led a company from incubation to a NASDAQ listing. Pancoast, an MBA from Harvard Business School, was joined by a team that includes scientific co-founders from the Albert Einstein College of Medicine, where the core technology was originally licensed.

The company's core offering is its patented Z-pod® technology, a topical delivery system using silica-derived microparticles to encapsulate active ingredients. This platform is designed to provide sustained, controlled release of therapeutic or cosmetic agents for over 24 hours, enhancing their bioavailability and duration of effect compared to traditional topical applications. Zylö refers to this as a "Patchless Patch™" concept, where the Z-pod® particles are integrated into standard creams or gels, embed in the outer layers of the skin, and gradually release their payload before naturally sloughing off. The particles can be manufactured at their Greenville, South Carolina facility and milled to various sizes to suit different formulations.

Zylö Therapeutics operates on a business-to-business model, primarily forging partnerships with companies in the pharmaceutical, cosmetic, and animal health industries. The company does not manufacture final consumer products but rather supplies its Z-pod® technology as a key ingredient, marketed with a 'Powered by Z-pod®' branding akin to 'Intel Inside'. This strategy has led to collaborations, such as the one with BosleyMD for a hair regrowth product line that incorporates the Z-pod® technology to deliver a proprietary active ingredient. Due to the broad applicability of its platform, Zylö spun out a new entity, Atticus Pharma, in 2024 to focus specifically on pharmaceutical applications, including treatments for alopecia and wound healing, while Zylö continues to serve the cosmetics and animal health markets.

The company has successfully secured funding through multiple rounds, including a $4 million Series A in 2019 and an oversubscribed $5.225 million Series B in 2022, with participation from investors like VentureSouth, New York Angels, and SC Launch. These funds have been allocated to scaling up the manufacturing of Z-pods®, implementing quality control systems like cGMP, and advancing internal research projects. The company has also received numerous government grants from the NIH for research into applications for conditions such as erectile dysfunction, cutaneous lupus, and onychomycosis.

Source: Dealroom company data

Zylö Therapeutics in the Greenville ecosystem

Live from Dealroom

The Zylö Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

10 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed3 investors entered at this stage

  • South Carolina Research Authority
  • VentureSouth
  • National Institute of Diabetes and Digestive and Kidney Diseases

Series A7 investors entered at this stage

  • Ariel Southeast Angel Partners
  • Chemical Angel Network
  • New York Angels
  • Boston Harbor Angels
  • James Cordes
  • HBS Alumni Angels of Greater New York
  • Cowtown Angels
Employees 4 total headcount
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇺🇸 United States100%
1 country shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Zylö Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Zylö Therapeutics on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.